The most expensive part of a cell therapy isn't the genetic payload. It's the factory. Extracting a patient's T cells, shipping them to a lab, engineering them, expanding them, and reinfusing them is a logistical and financial nightmare that limits these treatments to a handful of cancers and a tiny patient population. GigaMune, a San Francisco biotech founded in 2017, is betting it can skip the factory altogether by turning the patient's body into the bioreactor.
Its approach, which it calls "multiple-dose in vivo CAR-T," aims to deliver genetic instructions directly into a patient's T cells using engineered viral vectors [gigamune.com, retrieved 2024]. The goal is to create a cell therapy that can be administered like a traditional drug infusion, potentially opening the door to treating solid tumors and autoimmune diseases at scale. It's a high-risk, high-reward pivot from the company's original business of selling T-cell receptor discovery services to pharma companies.
The technical pivot
GigaMune began as a spinout from GigaGen, with a platform designed to identify rare, tumor-reactive T-cell receptors (TCRs) from patient samples [PRWeb, Apr 2020]. This service-oriented model was its initial commercial wedge. By 2020, the company was planning to develop TCR profiling for pharmaceutical customers while struggling to keep its expression libraries viable, according to an industry report [GenomeWeb, Apr 2020].
The shift to in-vivo delivery represents a fundamental change in technical strategy and business model. Instead of selling data or candidate receptors, GigaMune is now developing the therapeutic product itself. The core of this new approach is a proprietary lentivector, a type of virus engineered to safely deliver genetic material. In a preclinical lymphoma model, the company reported its vectors cleared 100% of tumors in 100% of mice [LinkedIn, retrieved 2026]. While animal data is far from a human guarantee, it provides the initial proof-of-concept required to secure further non-dilutive funding.
A grant-funded runway
GigaMune's financial trajectory is unusual for a venture-scale biotech. Rather than a traditional Series A, its progress has been measured in National Cancer Institute grant awards. The company has disclosed approximately $1.1 million in total funding, almost entirely from government sources.
| Date | Round/Type | Amount | Lead/Notable Details |
|---|---|---|---|
| Sep 2018 | NCI SBIR Grant | $300,000 | Supported cell therapy research based on tumor-infiltrating lymphocytes [PRWeb, Sep 2018]. |
| Apr 2019 | Angel/Convertible Debt | Undisclosed | From a group of technology and biotech CEOs [PRWeb, Apr 2019]. |
| Mar 2023 | Seed Financing | Undisclosed | Newsight Tech Angels reported as a participant [CB Insights, Mar 2023]. |
| Sep 2025 | NCI Project Grant | $800,000 | Awarded to develop a lentivector for in-vivo TCR delivery targeting stage-IV melanoma [GovTribe, Sep 2025]. |
This grant-heavy capitalization table suggests a capital-efficient, milestone-driven path. It has allowed the founders, David Johnson and Matthew Spindler, to advance the science without giving away significant equity early on. Both hold Ph.D.s and have deep roots in immunology and genomics; Spindler was the lead author on the company's 2020 paper in Nature Biotechnology [PRWeb, Apr 2020]. Johnson also serves as CEO of Genexa Inc., a separate company he co-founded in 2014 [genexa.com, retrieved 2026].
The competitive and commercial landscape
GigaMune is not alone in chasing in-vivo cell therapy. It lists competitors like GigaGen, Revitope, and Epitor Therapeutics, all working in adjacent spaces of immuno-oncology and TCR engineering. The commercial risk for GigaMune is twofold. First, it must prove its lentivector platform is safe and effective in humans, a hurdle that has felled countless biotechs. Second, it must navigate a business model transition from a service provider to a therapeutic developer.
Its early partnership with Massachusetts General Hospital for cell therapy development and a later collaboration with Champions Oncology to discover novel TCRs show an ability to engage with credible research institutions [PRWeb, Jul 2018][BioSpace, Feb 2022]. These relationships are valuable for validation, but they are not the same as a pharmaceutical partnership to co-develop a drug candidate.
The scale-up challenge
The technical breakdown of GigaMune's bet rests on a specific trade-off. Ex vivo cell therapy is brutally expensive but offers precise control over the engineered product. In vivo delivery is potentially cheaper and more scalable but introduces significant unknowns about dosing, targeting, and long-term safety.
- Vector tropism. The lentivector must reliably and selectively infect the right T cell subtypes in the body, not just in a mouse model.
- Dosing control. Administering genetic material directly into a patient requires a predictable relationship between the injected dose and the number of successfully engineered T cells, a complex pharmacokinetic challenge.
- Manufacturing at scale. While simpler than growing cells, producing clinical-grade lentiviral vectors at volume for late-stage trials is itself a formidable bioprocessing problem.
The sober assessment is that GigaMune's current non-dilutive funding is sufficient for preclinical work and early technical de-risking, but the capital required for an Investigational New Drug (IND) application and Phase I trials is orders of magnitude larger. The company's next twelve months will likely be defined by its ability to convert its compelling mouse data into the kind of results that attract a major strategic partner or a sizable venture round. The bet is clear: prove that turning the body into its own cell therapy factory isn't just a elegant concept, but a clinically and commercially viable platform.
Sources
- [gigamune.com, retrieved 2024] GigaMune, multiple-dose in vivo CAR-T | https://www.gigamune.com/
- [PRWeb, Apr 2020] GigaMune publishes results in Nature Biotechnology describing T-cell receptor discovery technology | https://www.prweb.com/releases/gigamune_publishes_results_in_nature_biotechnology_describing_t_cell_receptor_discovery_technology/prweb16990952.htm
- [GenomeWeb, Apr 2020] GigaMune Hopes to Offer TCR Screens to Pharmas While Scrambling to Keep Expression Libraries Alive | https://www.genomeweb.com/sequencing/gigamune-hopes-offer-tcr-screens-pharmas-while-scrambling-keep-expression-libraries-alive
- [LinkedIn, retrieved 2026] Post on lentivector results | https://www.linkedin.com/in/david-johnson-6329165a/
- [PRWeb, Sep 2018] GigaMune wins grant from National Cancer Institute to develop cell therapy based on tumor-infiltrating lymphocytes | https://www.prweb.com/releases/gigamune_wins_grant_from_national_cancer_institute_to_develop_cell_therapy_based_on_tumor_infiltrating_lymphocytes/prweb15743648.htm
- [PRWeb, Apr 2019] GigaMune closes angel financing to advance anti-tumor T cell receptor programs | https://www.prweb.com/releases/gigamune_closes_angel_financing_to_advance_anti_tumor_t_cell_receptor_programs/prweb16269382.htm
- [CB Insights, Mar 2023] GigaMune - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/gigamune
- [GovTribe, Sep 2025] Federal Grant Award: Project Grant R44CA310160 | https://govtribe.com/award/federal-grant-award/project-grant-r44ca310160
- [PRWeb, Jul 2018] GigaMune Secures Collaboration with Mass General for Development of Cell Therapies for Cancer | https://www.prweb.com/releases/GigaMune_Secures_Collaboration_with_Mass_General_for_Development_of_Cell_Therapies_for_Cancer/prweb15642764.htm
- [BioSpace, Feb 2022] Champions Oncology Announces a Partnership with GigaMune to Discover Novel Tumor-Reactive T Cell Receptors | https://www.biospace.com/champions-oncology-announces-a-partnership-with-gigamune-to-discover-novel-tumor-reactive-t-cell-receptors
- [genexa.com, retrieved 2026] Genexa company information | https://www.genexa.com/